Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lirentelimab (AK002), a humanized IgG1 monoclonal antibody, specifically targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It promotes apoptosis in IL-5-activated eosinophils and suppresses IgE-mediated activation of mast cells. This compound is under investigation for the treatment of eosinophilic gastritis and duodenitis [1].
説明 | Lirentelimab (AK002), a humanized IgG1 monoclonal antibody, specifically targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It promotes apoptosis in IL-5-activated eosinophils and suppresses IgE-mediated activation of mast cells. This compound is under investigation for the treatment of eosinophilic gastritis and duodenitis [1]. |
分子量 | N/A |
CAS No. | 2283348-97-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lirentelimab 2283348-97-8 Inhibitor inhibitor inhibit